Paul D. Ziegler
Research Subjects
Paul D. Ziegler has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Jodi L. Koehler
Medtronic Cardiac Rhythm Heart Failure, Mounds View, MN, United States
5 shared publicationsD. George Wyse
3 shared publicationsMichael D. Ezekowitz
3 shared publications- Atul Verma
McGill University Health Center, Montréal, Canada (A.V.).
2 shared publications Daniel E. Singer
2 shared publicationsEduardo Warman
Medtronic Mounds View MN United States
2 shared publications
Latest Publications
- Open Access
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
Objectives: To evaluate the cost-effectiveness of insertable cardiac monitors (ICMs) compared to standard of care (SoC) to detect atrial fibrillation (AF) in patients with stroke of presumed known cause of large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD) from a US payer perspective. Design: A lifetime Markov model assessed cost-effectiveness of ICM versus SoC from a US payer perspective. Patient characteristics and AF detection rates were based on the STROKE AF trial ( NCT02700945 ): 3-year diagnostic yield was 21.7% (95% CI 16.7% to 27.9%) for ICM and 2.4% (1.0%–5.7%) for SoC. AF detection resulted in a switch from aspirin to direct oral anticoagulant unless precluded by prior bleeding. Subsequent risks of ischaemic strokes (ISs) and bleeding events were modelled based on published literature. Costs and effects were discounted at 3% annually. Specific SoC short-term monitoring strategies (STMs) were explored as scenarios. Setting: US healthcare system perspective. Participants: Hypothetical cohort of patients with IS believed to be due to LAD or SVD. Interventions: Patients received an ICM within ten days of the index stroke or SoC involving conventional follow-up. Main outcome measures: Stroke and bleeding risk, mortality, health-related quality of life and healthcare cost and utilisation. Results: ICM was associated with a gain of 0.176 quality-adjusted life years (QALYs) compared with SoC per patient, representing a reduction of 53 strokes per 1000 patients. The lifetime incremental cost of ICM was $6736 per patient. This resulted in an estimated incremental cost-effectiveness ratio (ICER) of $38 346 per QALY gained, making ICM a cost-effective intervention at willingness-to-pay thresholds of $50 000–$150 000 per QALY in the USA. ICMs were also cost-effective compared with various individual STMs, with ICERs ranging from $29 814 to $38 941 per QALY gained. The mean probabilistic ICER across 5000 samples was $46 910 per QALY (97.5% CI$45 421 to $53 523). Results were sensitive to anticoagulant uptake on AF detection and underlying stroke risk. Model findings were robust to both probabilistic sensitivity analysis and sensitivity analyses where inputs tested were considered within plausible ranges, as ICM was found cost-effective in these analyses. Conclusions: ICMs are highly likely to be a cost-effective diagnostic tool for secondary prevention of stroke related to AF in US patients with prior stroke attributed to LAD or SVD. However, further research is needed to understand the efficacy of secondary stroke prevention treatments in patients with stroke attributed to LAD or SVD and subclinical AF.
Open AccessCost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA
Objectives: To evaluate the cost-effectiveness of insertable cardiac monitors (ICMs) compared to standard of care (SoC) to detect atrial fibrillation (AF) in patients with stroke of presumed known cause of large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD) from a US payer perspective. Design: A lifetime Markov model assessed cost-effectiveness of ICM versus SoC from a US payer perspective. Patient characteristics and AF detection rates were based on the STROKE AF trial ( NCT02700945 ): 3-year diagnostic yield was 21.7% (95% CI 16.7% to 27.9%) for ICM and 2.4% (1.0%–5.7%) for SoC. AF detection resulted in a switch from aspirin to direct oral anticoagulant unless precluded by prior bleeding. Subsequent risks of ischaemic strokes (ISs) and bleeding events were modelled based on published literature. Costs and effects were discounted at 3% annually. Specific SoC short-term monitoring strategies (STMs) were explored as scenarios. Setting: US healthcare system perspective. Participants: Hypothetical cohort of patients with IS believed to be due to LAD or SVD. Interventions: Patients received an ICM within ten days of the index stroke or SoC involving conventional follow-up. Main outcome measures: Stroke and bleeding risk, mortality, health-related quality of life and healthcare cost and utilisation. Results: ICM was associated with a gain of 0.176 quality-adjusted life years (QALYs) compared with SoC per patient, representing a reduction of 53 strokes per 1000 patients. The lifetime incremental cost of ICM was $6736 per patient. This resulted in an estimated incremental cost-effectiveness ratio (ICER) of $38 346 per QALY gained, making ICM a cost-effective intervention at willingness-to-pay thresholds of $50 000–$150 000 per QALY in the USA. ICMs were also cost-effective compared with various individual STMs, with ICERs ranging from $29 814 to $38 941 per QALY gained. The mean probabilistic ICER across 5000 samples was $46 910 per QALY (97.5% CI$45 421 to $53 523). Results were sensitive to anticoagulant uptake on AF detection and underlying stroke risk. Model findings were robust to both probabilistic sensitivity analysis and sensitivity analyses where inputs tested were considered within plausible ranges, as ICM was found cost-effective in these analyses. Conclusions: ICMs are highly likely to be a cost-effective diagnostic tool for secondary prevention of stroke related to AF in US patients with prior stroke attributed to LAD or SVD. However, further research is needed to understand the efficacy of secondary stroke prevention treatments in patients with stroke attributed to LAD or SVD and subclinical AF.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation
Background: Lower heart rates (HRs) prolong diastole, thereby raising filling pressures and wall stress (1,2), slowing myocardial relaxation (3), and increasing central blood pressure via superposition of reflected peripheral pressure waves onto systole (2,4). As a result, lower HRs may be associated with higher brain natriuretic peptide (BNP) levels and incident atrial fibrillation (AF). Beta-blockers (BBs) may thereby increase the risk for AF. Purpose: Examine the relationships of HR, BNP, BB use and new-onset AF in the REVEAL-AF and SPRINT cohort of subjects at risk for developing AF. Methods: In REVEAL-AF, 383 subjects (52% male, mean age 71.5±9.8 years) without a history of AF and a mean CHA2DS2VASC score of 4.4±1.3 received an insertable cardiac monitor and were followed up to 30 months. Baseline HRs were averaged between 8AM and 8PM for the first week post-implantation. Adjudicated AF lasting ≥6 minutes was defined as new-onset AF. In SPRINT, 7595 patients (64% male, mean age 67.5±9.2 years) without prior history of AF and a mean CHA2DS2VASC score of 2.3±1.2 were followed for up to 60 months. Baseline average HR was derived from three seated measurements taken at the initial clinical visit. 12-lead ECG at baseline, 2 years, 4 years and close-out visit were used to determine presence of AF. Based on longitudinal medication inventories BB use was categorized into “on BB” vs “never on BB” for the duration of the trial. Results: The median daytime HR in the REVEAL-AF cohort was 75bpm [interquartile range, IQR 68–83]. Subjects with below median HRs had 2.4-fold higher BNP levels when compared to subjects with above median HRs (median BNP [IQR]: 62pg/dl [37–112] vs. 26pg/dl [13–53], p<0.001). Below median HRs were associated with a higher incidence of AF: 37% vs. 27%, p=0.047. This was validated in the SPRINT cohort after adjusting for AF risk factors (age, HR, sex, body mass index, coronary artery disease, intensive vs standard blood pressure therapy, chronic kidney disease). Both a HR<75bpm and BB use were independently associated with a higher rate of AF: 1.9 vs 0.7%, p<0.001 and 2.5% vs. 0.6%, p<0.001, respectively. The hazard ratio for patients on BB to develop AF was 3.72 [CI 2.32, 5.96], p<0.001. Conclusion: Lower HRs and BB use are associated with higher BNP levels and incident AF, supporting the hypothesis that lower HRs mimic and/or exacerbate the hemodynamic effects of diastolic dysfunction and promote atrial myopathy. The effects of BBs on clinical outcomes in patient populations outside the context of heart failure with reduced ejection fraction will need to be reassessed. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Institute of Health
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation
Background: Lower heart rates (HRs) prolong diastole, thereby raising filling pressures and wall stress (1,2), slowing myocardial relaxation (3), and increasing central blood pressure via superposition of reflected peripheral pressure waves onto systole (2,4). As a result, lower HRs may be associated with higher brain natriuretic peptide (BNP) levels and incident atrial fibrillation (AF). Beta-blockers (BBs) may thereby increase the risk for AF. Purpose: Examine the relationships of HR, BNP, BB use and new-onset AF in the REVEAL-AF and SPRINT cohort of subjects at risk for developing AF. Methods: In REVEAL-AF, 383 subjects (52% male, mean age 71.5±9.8 years) without a history of AF and a mean CHA2DS2VASC score of 4.4±1.3 received an insertable cardiac monitor and were followed up to 30 months. Baseline HRs were averaged between 8AM and 8PM for the first week post-implantation. Adjudicated AF lasting ≥6 minutes was defined as new-onset AF. In SPRINT, 7595 patients (64% male, mean age 67.5±9.2 years) without prior history of AF and a mean CHA2DS2VASC score of 2.3±1.2 were followed for up to 60 months. Baseline average HR was derived from three seated measurements taken at the initial clinical visit. 12-lead ECG at baseline, 2 years, 4 years and close-out visit were used to determine presence of AF. Based on longitudinal medication inventories BB use was categorized into “on BB” vs “never on BB” for the duration of the trial. Results: The median daytime HR in the REVEAL-AF cohort was 75bpm [interquartile range, IQR 68–83]. Subjects with below median HRs had 2.4-fold higher BNP levels when compared to subjects with above median HRs (median BNP [IQR]: 62pg/dl [37–112] vs. 26pg/dl [13–53], p<0.001). Below median HRs were associated with a higher incidence of AF: 37% vs. 27%, p=0.047. This was validated in the SPRINT cohort after adjusting for AF risk factors (age, HR, sex, body mass index, coronary artery disease, intensive vs standard blood pressure therapy, chronic kidney disease). Both a HR<75bpm and BB use were independently associated with a higher rate of AF: 1.9 vs 0.7%, p<0.001 and 2.5% vs. 0.6%, p<0.001, respectively. The hazard ratio for patients on BB to develop AF was 3.72 [CI 2.32, 5.96], p<0.001. Conclusion: Lower HRs and BB use are associated with higher BNP levels and incident AF, supporting the hypothesis that lower HRs mimic and/or exacerbate the hemodynamic effects of diastolic dysfunction and promote atrial myopathy. The effects of BBs on clinical outcomes in patient populations outside the context of heart failure with reduced ejection fraction will need to be reassessed. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Institute of Health
- 1 September 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (9) , 2773-2781
Detection of Atrial Fibrillation After Central Retinal Artery Occlusion
Background: Central retinal artery occlusion (CRAO) causes sudden, irreversible blindness and is a form of acute ischemic stroke. In this study, we sought to determine the proportion of patients in whom atrial fibrillation (AF) is detected by extended cardiac monitoring after CRAO. Methods: We performed a retrospective, observational cohort study using data from the Optum deidentified electronic health record of 30.8 million people cross-referenced with the Medtronic CareLink database of 2.7 million people with cardiac monitoring devices in situ. We enrolled patients in 3 groups: (1) CRAO, (2) cerebral ischemic stroke, and (3) age-, sex-, and comorbidity-matched controls. The primary end point was the detection of new AF (defined as ≥2 minutes of AF detected on a cardiac monitoring device). Results: We reviewed 884 431 patient records in common between the two databases to identify 100 patients with CRAO, 6559 with ischemic stroke, and 1000 matched controls. After CRAO, the cumulative incidence of new AF at 2 years was 49.6% (95% CI, 37.4%–61.7%). Patients with CRAO had a higher rate of AF than controls (hazard ratio, 1.64 [95% CI, 1.17–2.31]) and a comparable rate to patients with stroke (hazard ratio, 1.01 [95% CI, 0.75–1.36]). CRAO was associated with a higher incidence of new stroke compared with matched controls (hazard ratio, 2.85 [95% CI, 1.29–6.29]). Conclusions: The rate of AF detection after CRAO is higher than that seen in age-, sex-, and comorbidity-matched controls and comparable to that seen after ischemic cerebral stroke. Paroxysmal AF should be considered as part of the differential etiology of CRAO, and those patients may benefit from long-term cardiac monitoring.
- 1 September 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (9) , 2773-2781
Detection of Atrial Fibrillation After Central Retinal Artery Occlusion
Background: Central retinal artery occlusion (CRAO) causes sudden, irreversible blindness and is a form of acute ischemic stroke. In this study, we sought to determine the proportion of patients in whom atrial fibrillation (AF) is detected by extended cardiac monitoring after CRAO. Methods: We performed a retrospective, observational cohort study using data from the Optum deidentified electronic health record of 30.8 million people cross-referenced with the Medtronic CareLink database of 2.7 million people with cardiac monitoring devices in situ. We enrolled patients in 3 groups: (1) CRAO, (2) cerebral ischemic stroke, and (3) age-, sex-, and comorbidity-matched controls. The primary end point was the detection of new AF (defined as ≥2 minutes of AF detected on a cardiac monitoring device). Results: We reviewed 884 431 patient records in common between the two databases to identify 100 patients with CRAO, 6559 with ischemic stroke, and 1000 matched controls. After CRAO, the cumulative incidence of new AF at 2 years was 49.6% (95% CI, 37.4%–61.7%). Patients with CRAO had a higher rate of AF than controls (hazard ratio, 1.64 [95% CI, 1.17–2.31]) and a comparable rate to patients with stroke (hazard ratio, 1.01 [95% CI, 0.75–1.36]). CRAO was associated with a higher incidence of new stroke compared with matched controls (hazard ratio, 2.85 [95% CI, 1.29–6.29]). Conclusions: The rate of AF detection after CRAO is higher than that seen in age-, sex-, and comorbidity-matched controls and comparable to that seen after ischemic cerebral stroke. Paroxysmal AF should be considered as part of the differential etiology of CRAO, and those patients may benefit from long-term cardiac monitoring.
- 1 August 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (8)
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype
Background: Bucindolol is a genetically targeted β-blocker/mild vasodilator with the unique pharmacological properties of sympatholysis and ADRB1 Arg389 receptor inverse agonism. In the GENETIC-AF trial (Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for the Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure) conducted in a genetically defined heart failure population at high risk for recurrent atrial fibrillation (AF), similar results were observed for bucindolol and metoprolol succinate for the primary end point of time to first AF event; however, AF burden and other rhythm control measures were not analyzed. Methods: The prevalence of ECGs in normal sinus rhythm, AF interventions for rhythm control (cardioversion, ablation, and antiarrhythmic drugs) and biomarkers were evaluated in the overall population entering efficacy follow-up (N=257). AF burden was evaluated for 24 weeks in the device substudy (N=67). Results: In 257 patients with heart failure, the mean age was 65.6±10.0 years, 18% were female, mean left ventricular ejection fraction was 36%, and 51% had persistent AF. Cumulative 24-week AF burden was 24.4% (95% CI, 18.5–30.2) for bucindolol and 36.7% (95% CI, 30.0–43.5) for metoprolol (33% reduction, P P P P =0.011). Reductions in plasma norepinephrine ( P =0.038) and NT-proBNP (N-terminal pro B-type natriuretic peptide; P =0.009) were also observed with bucindolol compared with metoprolol. Conclusions: Compared with metoprolol, bucindolol reduced AF burden, improved maintenance of sinus rhythm, and lowered the need for additional rhythm control interventions in patients with heart failure and the ADRB1 Arg389Arg genotype. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01970501.
- 1 August 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (8)
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype
Background: Bucindolol is a genetically targeted β-blocker/mild vasodilator with the unique pharmacological properties of sympatholysis and ADRB1 Arg389 receptor inverse agonism. In the GENETIC-AF trial (Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for the Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure) conducted in a genetically defined heart failure population at high risk for recurrent atrial fibrillation (AF), similar results were observed for bucindolol and metoprolol succinate for the primary end point of time to first AF event; however, AF burden and other rhythm control measures were not analyzed. Methods: The prevalence of ECGs in normal sinus rhythm, AF interventions for rhythm control (cardioversion, ablation, and antiarrhythmic drugs) and biomarkers were evaluated in the overall population entering efficacy follow-up (N=257). AF burden was evaluated for 24 weeks in the device substudy (N=67). Results: In 257 patients with heart failure, the mean age was 65.6±10.0 years, 18% were female, mean left ventricular ejection fraction was 36%, and 51% had persistent AF. Cumulative 24-week AF burden was 24.4% (95% CI, 18.5–30.2) for bucindolol and 36.7% (95% CI, 30.0–43.5) for metoprolol (33% reduction, P P P P =0.011). Reductions in plasma norepinephrine ( P =0.038) and NT-proBNP (N-terminal pro B-type natriuretic peptide; P =0.009) were also observed with bucindolol compared with metoprolol. Conclusions: Compared with metoprolol, bucindolol reduced AF burden, improved maintenance of sinus rhythm, and lowered the need for additional rhythm control interventions in patients with heart failure and the ADRB1 Arg389Arg genotype. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01970501.
- 1 January 2020
- Published by Elsevier in American Heart Journal
- Vol. 219, 128-136
Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study
- 1 January 2020
- Published by Elsevier in American Heart Journal
- Vol. 219, 128-136
Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study
- 10 September 2018
- Published by SAGE Publications in International Journal of Stroke
- Vol. 14 (2) , 146-153
Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors
Background: Prophylactic use of direct oral anticoagulants for recurrent stroke prevention in patients with embolic strokes of undetermined source is currently being investigated. It is uncertain whether the bleeding risks associated with prophylactic direct oral anticoagulants use will outweigh any stroke prevention benefit in embolic strokes of undetermined source patients who lack underlying atrial fibrillation. Methods: We determined the proportion of cryptogenic stroke patients in the CRYSTAL atrial fibrillation trial who met inclusion criteria for the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials and their atrial fibrillation incidence. Both embolic strokes of undetermined source trials impose requirements on age, modified Rankin Score, antiplatelet use, and type of infarction. Insertable cardiac monitors were used to determine the atrial fibrillation detection rates at 30 days and 3 years using Kaplan–Meier’s estimates. Results: Among 441 patients enrolled in the CRYSTAL atrial fibrillation trial, 189 (42.9%) and 236 (53.5%) met the inclusion criteria of the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials, respectively. Atrial fibrillation detection rates at 3 years among insertable cardiac monitors patients eligible for the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials were 35.8% and 33.6% while detection rates at 30 days were 5.6% and 3.5%, respectively. Conclusion: Only half of cryptogenic stroke patients in CRYSTAL atrial fibrillation met the inclusion criteria for the ongoing embolic strokes of undetermined source trials. Approximately, two-thirds of patients with embolic strokes of undetermined source do not have any atrial fibrillation despite continuous rhythm monitoring for up to three years. The benefits of prophylactic use of direct oral anticoagulants in the absence of atrial fibrillation is unknown and therefore embolic strokes of undetermined source patients could benefit from prolonged atrial fibrillation monitoring until more robust data are available. ClinicalTrials.gov Registration: NCT00924638. https://clinicaltrials.gov/ct2/show/NCT00924638 .
- 10 September 2018
- Published by SAGE Publications in International Journal of Stroke
- Vol. 14 (2) , 146-153
Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors
Background: Prophylactic use of direct oral anticoagulants for recurrent stroke prevention in patients with embolic strokes of undetermined source is currently being investigated. It is uncertain whether the bleeding risks associated with prophylactic direct oral anticoagulants use will outweigh any stroke prevention benefit in embolic strokes of undetermined source patients who lack underlying atrial fibrillation. Methods: We determined the proportion of cryptogenic stroke patients in the CRYSTAL atrial fibrillation trial who met inclusion criteria for the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials and their atrial fibrillation incidence. Both embolic strokes of undetermined source trials impose requirements on age, modified Rankin Score, antiplatelet use, and type of infarction. Insertable cardiac monitors were used to determine the atrial fibrillation detection rates at 30 days and 3 years using Kaplan–Meier’s estimates. Results: Among 441 patients enrolled in the CRYSTAL atrial fibrillation trial, 189 (42.9%) and 236 (53.5%) met the inclusion criteria of the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials, respectively. Atrial fibrillation detection rates at 3 years among insertable cardiac monitors patients eligible for the NAVIGATE embolic stroke of undetermined source and RE-SPECT embolic stroke of undetermined source trials were 35.8% and 33.6% while detection rates at 30 days were 5.6% and 3.5%, respectively. Conclusion: Only half of cryptogenic stroke patients in CRYSTAL atrial fibrillation met the inclusion criteria for the ongoing embolic strokes of undetermined source trials. Approximately, two-thirds of patients with embolic strokes of undetermined source do not have any atrial fibrillation despite continuous rhythm monitoring for up to three years. The benefits of prophylactic use of direct oral anticoagulants in the absence of atrial fibrillation is unknown and therefore embolic strokes of undetermined source patients could benefit from prolonged atrial fibrillation monitoring until more robust data are available. ClinicalTrials.gov Registration: NCT00924638. https://clinicaltrials.gov/ct2/show/NCT00924638 .
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 125: Validation of a Clinical Risk Score for Predicting Atrial Fibrillation in Cryptogenic Stroke Patients With Insertable Cardiac Monitors: Insights From the CRYSTAL AF Study
Introduction: Insertable cardiac monitors (ICMs) have been shown to be superior to standard monitoring for the detection of underlying atrial fibrillation (AF) in patients (pts) with cryptogenic stroke (CS). However, identifying a subset of CS pts who would benefit most from ICMs is desirable. We evaluated whether a recently developed risk score for the prediction of clinically-detected AF in CS pts (the HAVOC score) also predicted the presence of subclinical AF as detected by ICMs. Methods: Pts who received an ICM in the CRYSTAL AF study were included. HAVOC scores were retrospectively calculated by assigning points based on the presence of hypertension (2), age ≥75 (2), valvular disease (2), vascular disease (1), obesity (1), congestive heart failure (4), and coronary artery disease (2), resulting in scores from 0-14 with pts assigned to Group A (0-1), B (2-3), or C (≥4) based on their score. The ICM monitored cardiac rhythm continuously for up to 3 years to identify the presence of AF. AF detected by the ICM (≥2 minutes) was correlated with HAVOC score groupings via the chi-square test. Results: A total of 214 ICM pts (mean age 61±11 years, 66% male) were followed for 1.8±0.7 years. Mean and median HAVOC scores were 2.4±2.6 and 2 [1-3], respectively, with 89% having scores ≤4. The AF detection rate at 3 years was 27%. Mean HAVOC scores tended to be higher among pts with vs. without AF detected (2.9±1.8 vs. 2.3±2.1, p=0.07). The proportion of patients with AF increased significantly from 11% to 18% to 32% as HAVOC scores progressed from Groups A to B to C, respectively (p=0.02). Conclusions: In a cohort of CS pts with ICMs, the prevalence of AF increased significantly with increasing HAVOC score groups. This parameter should be considered when comparing AF detection rates between different studies, as the vast majority of CRYSTAL AF pts had very low HAVOC scores. Further validation of this risk score in CS pts with ICMs is warranted across a broader spectrum of risk measured by this novel score.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 125: Validation of a Clinical Risk Score for Predicting Atrial Fibrillation in Cryptogenic Stroke Patients With Insertable Cardiac Monitors: Insights From the CRYSTAL AF Study
Introduction: Insertable cardiac monitors (ICMs) have been shown to be superior to standard monitoring for the detection of underlying atrial fibrillation (AF) in patients (pts) with cryptogenic stroke (CS). However, identifying a subset of CS pts who would benefit most from ICMs is desirable. We evaluated whether a recently developed risk score for the prediction of clinically-detected AF in CS pts (the HAVOC score) also predicted the presence of subclinical AF as detected by ICMs. Methods: Pts who received an ICM in the CRYSTAL AF study were included. HAVOC scores were retrospectively calculated by assigning points based on the presence of hypertension (2), age ≥75 (2), valvular disease (2), vascular disease (1), obesity (1), congestive heart failure (4), and coronary artery disease (2), resulting in scores from 0-14 with pts assigned to Group A (0-1), B (2-3), or C (≥4) based on their score. The ICM monitored cardiac rhythm continuously for up to 3 years to identify the presence of AF. AF detected by the ICM (≥2 minutes) was correlated with HAVOC score groupings via the chi-square test. Results: A total of 214 ICM pts (mean age 61±11 years, 66% male) were followed for 1.8±0.7 years. Mean and median HAVOC scores were 2.4±2.6 and 2 [1-3], respectively, with 89% having scores ≤4. The AF detection rate at 3 years was 27%. Mean HAVOC scores tended to be higher among pts with vs. without AF detected (2.9±1.8 vs. 2.3±2.1, p=0.07). The proportion of patients with AF increased significantly from 11% to 18% to 32% as HAVOC scores progressed from Groups A to B to C, respectively (p=0.02). Conclusions: In a cohort of CS pts with ICMs, the prevalence of AF increased significantly with increasing HAVOC score groups. This parameter should be considered when comparing AF detection rates between different studies, as the vast majority of CRYSTAL AF pts had very low HAVOC scores. Further validation of this risk score in CS pts with ICMs is warranted across a broader spectrum of risk measured by this novel score.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study
Introduction: Recent trials using insertable cardiac monitors (ICMs) show high rates of atrial fibrillation (AF) in those at risk of developing AF based on demographics. Further identifying subsets who could benefit most from ICMs is desirable. We evaluated if the recently-developed HAVOC risk score which has predicted AF in cryptogenic stroke patients also predicts AF detection by ICMs in those without a recent stroke. Methods: Participants from the prospective REVEAL AF study, which reported frequent clinically unrecognized AF in patients at risk for AF (CHADS 2 scores ≥3 or =2 with ≥1 additional risk factor), with ICM data and not on anti-arrhythmic drugs were included. Ischemic stroke 0.05, median time from stroke to ICM insertion=4 years). Conclusions: The HAVOC risk score identified a subset of high risk individuals at greatest risk of developing AF. AF incidence rates were similar among those with and without prior remote stroke. Remote strokes may not be a strong predictor of AF in this population. HAVOC scores could be a useful approach to identify those at high likelihood of manifesting AF, as best documented by long-term monitoring.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study
Introduction: Recent trials using insertable cardiac monitors (ICMs) show high rates of atrial fibrillation (AF) in those at risk of developing AF based on demographics. Further identifying subsets who could benefit most from ICMs is desirable. We evaluated if the recently-developed HAVOC risk score which has predicted AF in cryptogenic stroke patients also predicts AF detection by ICMs in those without a recent stroke. Methods: Participants from the prospective REVEAL AF study, which reported frequent clinically unrecognized AF in patients at risk for AF (CHADS 2 scores ≥3 or =2 with ≥1 additional risk factor), with ICM data and not on anti-arrhythmic drugs were included. Ischemic stroke 0.05, median time from stroke to ICM insertion=4 years). Conclusions: The HAVOC risk score identified a subset of high risk individuals at greatest risk of developing AF. AF incidence rates were similar among those with and without prior remote stroke. Remote strokes may not be a strong predictor of AF in this population. HAVOC scores could be a useful approach to identify those at high likelihood of manifesting AF, as best documented by long-term monitoring.
- Open Access
- 1 October 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 244, 175-179
Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population
- 1 October 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 244, 175-179
Open AccessLong-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population